SOPs for Biosimilars V 2.0

To define a validated procedure for testing endotoxin levels in biosimilar cell culture media, buffers, and harvested fluids using the Limulus Amebocyte Lysate (LAL) assay to ensure product safety and compliance.
Click to read the full article.

To define the procedure for evaluating and validating viral clearance from biosimilar-producing cell lines by applying virus inactivation and removal steps during upstream and downstream processing, as per ICH Q5A and WHO guidelines.
Click to read the full article.

To define the procedure for optimizing cell culture media used for biosimilar production, aimed at improving cell growth, viability, product yield, and critical quality attributes (CQAs).
Click to read the full article.

To define the procedure for evaluating the expression of biosimilar-producing clones in small-scale formats to determine protein titer, cell growth characteristics, and product quality prior to scale-up.
Click to read the full article.

To define the procedure for conducting stability studies on engineered biosimilar-producing clones to assess their genetic and expression stability during prolonged culture, storage, and production cycles.
Click to read the full article.

To define the procedures for conducting comprehensive biosafety assessment of mammalian cell lines used in biosimilar manufacturing, ensuring compliance with global regulatory standards for sterility, mycoplasma, and viral contamination.
Click to read the full article.

To define the procedure for the safe handling, containment, documentation, and disposal of Genetically Modified Organisms (GMOs) used during biosimilar R&D and manufacturing, as per Indian and international biosafety regulations.
Click to read the full article.

To establish a standardized procedure for record keeping and documentation during cell line development (CLD) for biosimilars to ensure traceability, reproducibility, and regulatory compliance in line with GMP and data integrity principles.
Click to read the full article.

To establish a systematic procedure for risk assessment associated with genetic engineering operations during biosimilar development, including evaluation of biological hazards, vector-host systems, gene inserts, and containment strategies in accordance with applicable biosafety and regulatory guidelines.
Click to read the full article.

To define the procedure for complying with national and international regulations governing the use of Genetically Modified Organisms (GMOs) in biosimilar research and development, ensuring legal authorization, risk control, and biosafety documentation.
Click to read the full article.